Biofrontera Inc. (BFRI) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BFRI Revenue Growth
Revenue Breakdown (FY 2023)
BFRI's revenue distribution by segment and geography for fiscal year 2023
By Product/Segment
BFRI Revenue Analysis (2019–2025)
As of May 8, 2026, Biofrontera Inc. (BFRI) generated trailing twelve-month (TTM) revenue of $41.7 million, reflecting explosive growth of +36.2% year-over-year. The most recent quarter (Q4 2025) recorded $17.1 million in revenue, up 144.7% sequentially.
Looking at the longer-term picture, BFRI's 5-year compound annual growth rate (CAGR) stands at +17.2%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $41.7 million in 2025, representing a new all-time high.
Revenue diversification analysis shows BFRI's business is primarily driven by Government and Payor Rebates (58%), Co-pay Assistance Program (31%), and Returns (10%). With over half of revenue concentrated in Government and Payor Rebates, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including DERM (-27.4% YoY), PRGO (-3.6% YoY), and NVCR (+8.5% YoY), BFRI has outperformed the peer group in terms of revenue growth. Compare BFRI vs DERM →
BFRI Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BFRICurrent | $42M | +36.2% | +17.2% | -27.2% | |
 DERM | $56M | -27.4% | +10.0% | -24.4% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 GDRX | $797M | -1.2% | +7.7% | 13.4% | |
 SKIN | $301M | -8.2% | +20.4% | -6.9% |
BFRI Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $41.7M | +11.8% | $31.6M | 75.8% | $-11,348,000 | -27.2% |
| 2024 | $37.3M | +9.5% | $18.7M | 50.1% | $-17,210,000 | -46.1% |
| 2023 | $34.1M | +18.8% | $16.6M | 48.8% | $-22,677,000 | -66.6% |
| 2022 | $28.7M | +19.0% | $13.5M | 47.0% | $-18,581,000 | -64.8% |
| 2021 | $24.1M | +27.9% | $11.4M | 47.1% | $-25,201,000 | -104.6% |
| 2020 | $18.8M | -28.0% | $9.8M | 51.9% | $-9,606,000 | -51.0% |
| 2019 | $26.2M | - | $13.8M | 52.6% | $-14,922,000 | -57.0% |
See BFRI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BFRI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BFRI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBFRI — Frequently Asked Questions
Quick answers to the most common questions about buying BFRI stock.
Is BFRI's revenue growth accelerating or slowing?
BFRI revenue is accelerating at +36.2% year-over-year, exceeding the 5-year CAGR of +17.2%. TTM revenue reached $42M. Growth momentum has increased versus prior periods.
What is BFRI's long-term revenue growth rate?
Biofrontera Inc.'s 5-year revenue CAGR of +17.2% reflects the sustained expansion pattern. Current YoY growth of +36.2% is above this long-term average.
How is BFRI's revenue distributed by segment?
BFRI reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.